Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro.
We have demonstrated that fluoroquinolones, a class of antibacterial agents that act through inhibition of type II DNA topoisomerases, exert selective action against intracellular amastigotes of Leishmania (Viannia) panamensis at concentrations that are achievable in vivo. Drug cytotoxicity assays employing the luciferase reporter gene revealed that intracellular amastigotes were 6.6- to 25.9-fold more sensitive than human macrophages (P < 0.05) to second-generation fluoroquinolones in vitro. The most selective agents (enoxacin and ciprofloxacin) exhibited 2 orders of magnitude greater potency against parasites (50% effective dose [ED50] = 54.9-83.4 microM) than host cells (ED50 = 1,425-1,740 microM). Linear regression analysis of ED50 data confirmed a complete lack of correlation (r = 0.001) between the relative drug sensitivities of parasites and host cells. A potential relationship between the structures of fluoroquinolones and their relative leishmanicidal activities was observed. The key substituents of the basic pyridone beta-carboxylic acid nucleus accounting for enhanced antiparasite potency and selectivity appear to be a nitrogen at position 8 of the bicyclic nucleus (enoxacin), a cyclopropyl substituent at the R1 site (ciprofloxacin), and linkage of the R1 and X8 groups by a CH3CHO bridge to form a tricyclic compound (ofloxacin). These findings support the potential of fluoroquinolones and derivatives as novel antileishmanials and encourage their clinical evaluation.
Centro Internacional de Entrenamiento e Investigaciones Médicas, Cali, Colombia.
Ibeth C
IC
Romero
Nancy G
NG
Saravia
John
J
Walker
D000818:Animals; D002460:Cell Line; D002937:Cinoxacin / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D015365:Enoxacin / Q000494:pharmacology; D024841:Fluoroquinolones / Q000494:pharmacology*; D006801:Humans; D018334:Leishmania guyanensis / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects / Q000469:parasitology*; D009268:Nalidixic Acid / Q000494:pharmacology; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology
D024841:Fluoroquinolones; D015363:Quinolones; D015365:Enoxacin; D009268:Nalidixic Acid; D002939:Ciprofloxacin; D015242:Ofloxacin; C053091:lomefloxacin; D002937:Cinoxacin; D009643:Norfloxacin